| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,834,746 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-05-14 |
4 |
AS |
$18.01 |
$900,295 |
D/D |
(50,000) |
1,553,935 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-04-17 |
4 |
AS |
$18.00 |
$97,201 |
I/I |
(5,400) |
22,057 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-04-17 |
4 |
AS |
$18.01 |
$1,800,590 |
D/D |
(100,000) |
1,667,521 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$76,665 |
D/D |
(4,250) |
62,275 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$43,295 |
D/D |
(2,400) |
57,682 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-04-02 |
4 |
S |
$18.05 |
$43,327 |
D/D |
(2,400) |
117,871 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$93,813 |
D/D |
(5,200) |
199,355 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2013-04-02 |
4 |
S |
$18.05 |
$46,625 |
D/D |
(2,583) |
54,096 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$61,339 |
D/D |
(3,400) |
73,907 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$117,245 |
D/D |
(6,500) |
363,705 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2013-04-02 |
4 |
S |
$18.05 |
$43,322 |
D/D |
(2,400) |
208,898 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
66,525 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
60,082 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
120,271 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-04-01 |
4 |
D |
$18.30 |
$360,290 |
D/D |
(19,688) |
1,767,521 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
41,666 |
1,787,209 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
204,555 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,166 |
56,679 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
77,307 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
370,205 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
211,298 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-03-26 |
4 |
S |
$18.75 |
$242,492 |
D/D |
(12,933) |
191,555 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2013-03-25 |
4 |
S |
$18.87 |
$248,482 |
D/D |
(13,167) |
51,513 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-03-25 |
4 |
S |
$18.87 |
$361,766 |
D/D |
(19,167) |
357,205 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-03-25 |
4 |
S |
$18.88 |
$100,672 |
D/D |
(5,333) |
68,807 |
|
- |
|
703 Records found
|
|
Page 14 of 29 |
|
|
